Heather White
Chief Tech/Sci/R&D Officer at ALBIREO PHARMA, INC.
Heather White active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALBIREO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2023-03-01 | - |
Career history of Heather White
Former positions of Heather White
| Companies | Position | Start | End |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC. | Director/Board Member | 2007-12-31 | - |
Schering-Plough Ltd.
 Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Chief Tech/Sci/R&D Officer | 1996-12-31 | - |
| IPSEN | Comptroller/Controller/Auditor | 2013-12-31 | - |
Training of Heather White
| The University of Liverpool | Graduate Degree |
Statistics
International
| United Kingdom | 3 |
| United States | 3 |
| France | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Comptroller/Controller/Auditor | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| IPSEN | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Schering-Plough Ltd.
Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Heather White
- Experience
